Potential
to Address Major U.S. and Global Need
It’s
one of the single most sought-after drugs in the medical industry, and
biotechnology company VistaGen Therapeutics may have it. What is so desperately
needed is a drug able to treat a disease that afflicts tens of millions of
people in the U.S., and hundreds of millions globally. The disease is MDD
(Major Depressive Disorder), a crippling form of depression that is not
effectively treated by existing medications. It is now recognized as a disease
that seriously undermines economies and society as a whole, contributing to
hundreds of thousands of deaths worldwide each year. The recent death of actor
and comedian Robin Williams has shed a public light on the gravity of
individual depression, but researchers know that it affects as many as one out
of 20 households. They also know the significant issues with standard
treatments for MDD.
Current
Drugs Too Slow or With Side Effects
Traditional
FDA-approved drugs currently used to treat depression are very slow acting, a
consequence of the way they operate in the brain. It can take weeks or even
months to achieve the intended benefit of these antidepressants, time that
patients experiencing an MDD crisis often don’t have. The lack of noticeable
and timely results with such treatments can easily discourage people with MDD
from continuing with their antidepressant medications. In desperation a patient
can slide from one drug to another until they feel they’ve run out of options,
potentially with fatal results.
So
anxious is the medical establishment for an effective quick-acting
anti-depressant that ketamine, a multi-purpose pain killer and anesthetic, has
been re-purposed by certain physicians as an anti-depressant, primarily because
of its ability to deliver rapid, robust antidepressant effects in MDD patients.
An article in Scientific American (http://dtn.fm/gkE0) talked about how the
ketamine’s promise has ignited excitement among clinicians and neuroscientists,
in spite of its associated adverse effects, pointing out that “a person taking
ketamine may experience altered physical, spatial and temporal states; larger
quantities may induce hallucinations and dissolution of the self”. Over and
above what an article in Nature Reviews (http://dtn.fm/4LjI) called
“psychosis-like side effects”, another major problem with ketamine is that it
must be given intravenously. Forcing patients to get frequent infusions to
stave off depression is nobody’s idea of an optimum solution, but it
underscores the serious, unmet medical need in this area.
New
Drug May Be Perfect Storm
Amidst
all of this has come a highly innovative new approach from California-based
VistaGen Therapeutics, a biopharmaceutical company known primarily for its stem
cell technology. VistaGen’s novel, orally available MDD drug candidate AV-101
is ready for Phase 2 clinical development in the U.S. and is starting to look
like a very big deal, because it offers the promise of being an antidepressant
that is both powerful and quick-acting, while at the same time causing none of
the mind-bending side effects of ketamine. The drug operates in a different way
than the other FDA-approved antidepressant drugs, providing a much more
moderated effect while still getting the job done. NIH sponsored Phase 1
studies of AV-101 have already shown it to be a remarkably safe and
well-tolerated compound. Perhaps even more notable is the fact that AV-101 can
be taken orally, with no need for regular injections or IV administration. It’s
an almost ideal combination of properties, with a multi-billion dollar market
on the table.
From
a technical standpoint, AV-101 (4-Cl-KYN) is an orally-available, non-sedating,
non-hallucinogenic prodrug (precursor drug) that is rapidly and enzymatically
converted to its active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), one of
the most well-characterized, potent, and selective synthetic blockers of
N-methyl-D-aspartate (NMDA) receptors at the glycine-coagonist (GlyB) site.
Although the pathophysiology of depression has been linked to monoaminergic
mechanisms for decades, compelling evidence now suggests a key role of the
glutamatergic system in mood disorders and favors the idea that AV-101’s
targeted antagonism of the glycineB site of the NMDA receptor can provide
rapid, robust antidepressant effects in treatment of MDD similar to ketamine,
but without ketamine’s serious side effects.
VistaGen
is currently preparing for a Phase 2 MDD study in early 2015, so keep an eye
open for announcements.
In
addition to MDD, AV-101 is now also being seen as a potential treatment for
other diseases involving the central nervous system, including epilepsy,
chronic neuropathic pain, and neurodegenerative disorders such as Parkinson’s
disease.
For
additional information, visit the company’s website at www.vistagen.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign
up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please
see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment